Thanh bên bài viết

PDF
Ngày xuất bản: 28/04/2025
Số lượt xem tóm tắt: 67
Số lượt xem PDF: 160
Số xuất bản
Tập 50 Số 4 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 4 - 2025
Chuyên mục
Bài báo
Trích dẫn bài báo
Dao, T. T. T., Nguyen, D. T., Quach, T. D., Yi, Y. H. G., Dinh, T. V. A., & Le, V. D. (2025). A CASE REPORT: HER2-TARGETED THERAPY IN COLORECTAL CANCER. Tạp chí Y Dược học Quân sự, 50(4), 129-135. https://jmpm.vn/index.php/jmpm/article/view/1178

A CASE REPORT: HER2-TARGETED THERAPY IN COLORECTAL CANCER

Dao Thi Thu Trang1, Nguyen Dinh Tung1, Quach Thanh Dung1, Yi Yi Hyeon Gyu2, Dinh Thi Van Anh3, Le Vu Duy4,
1 Hematology - Oncology Department, Vinmec Times City International Hospital
2 Oncology Center, Vinmec Central Park International Hospital
3 Functional Rehabilitation Department, Military Hospital 103, Vietnam Military Medical University
4 Radiology Center, Military Hospital 103, Vietnam Military Medical University

Nội dung chính của bài viết

Tóm tắt

Colorectal cancer (CRC) is a malignant tumor arising from the inner lining of the colon or rectum and is the third most common cancer and the third leading cause of cancer-related deaths in the United States. Human epidermal growth factor receptor 2 (HER2) gene overexpressed or amplified CRC has shown treatment responses with HER2-targeted therapies. This article reports two cases of heavily pretreated metastatic CRC (mCRC) with HER2 overexpression who achieved a remarkable clinical response to trastuzumab plus pertuzumab.

Chi tiết bài viết

Từ khóa

Human epidermal growth factor receptor 2 (HER2), Anti-HER2 therapy, Trastuzumab plus pertuzumab, Colorectal cancer

Tài liệu tham khảo

1. Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014; 111(10):1977-1984.
2. Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. PloS One. 2014; 9(5):e98528.
3. Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018; 124(7):1358-1373.
4. Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. The Oncologist. 2019; 24(10):1395-1402.
5. Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016; 238(4):562-570.
6. Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019; 3:1-13.
7. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. Mod Pathol Off J U S Can Acad Pathol Inc. 2015; 28(11):1481-1491.
8. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol Off J Eur Soc Med Oncol. 2001; 12(1):S9-13.
9. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019; 20(4):518-530.
10. Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: A phase 2 trial. Nat Med. 2021; 27(11):1899-1903.